Natco Pharma net profit down 23.44 percent at Rs 517.9 crore in Q2
New Delhi: Natco Pharma has announced a 23.44 percent drop in its consolidated net profit for the second quarter ending September 30, 2025. The company reported a consolidated net profit of Rs 517.9 crore, compared to Rs 676.5 crore in the same period of the previous fiscal year.
The decline was attributed to higher research and development (R&D) expenses and a one-time employee bonus.
Consolidated revenue from operations in the second quarter stood at Rs 1,363 crore, as against Rs 1,371.1 crore in the corresponding period last fiscal, it added.
Read also: Natco Pharma acquires 35.75% stake in Adcock Ingram for USD 226 million
NATCO Pharma Limited is a public limited company, listed on the Bombay Stock Exchange and the National Stock Exchange of India, with a market capitalisation of c. US$ 2 billion. Established in 1981, NATCO Pharma has evolved into a diversified pharmaceutical manufacturer, with a primary focus on research and development, manufacturing, and global marketing of both finished dosage formulations and active pharmaceutical ingredients. NATCO Pharma operates across various geographies (in over 50 countries), including emerging and developed markets, with a particular focus on delivering quality medicines in oncology, cardiology, neurology, and other high-value therapeutic categories.
